CDX
NCI-H929
Tumor indication
Lymphoid
Tumor subtype
Multiple Myeloma
Description
NCI-H929 (Multiple Myeloma CDX Model)
The NCI-H929 line was derived from a patient with multiple myeloma. It represents plasma cell malignancies and secretes immunoglobulin. NCI-H929 is widely used in drug testing and biomarker research. Its reproducibility makes it a standard in translational hematology.
Key Features:
- Derived from multiple myeloma.
- Produces immunoglobulin.
- B-cell plasma phenotype.
- Tumorigenic in xenografts.
Applications:
NCI-H929 supports evaluation of novel therapeutics for multiple myeloma. Researchers use it in biomarker and resistance studies. It is also applied in drug discovery targeting malignant plasma cells. Its reproducibility ensures reliability in hematology pipelines.
Details
- Tumor indication
- Lymphoid
- Tumor subtype
- Multiple Myeloma
- Organism
- Human
- Mouse sex
- Female
- Lumin data
- Proteomics, RNA-Seq, WES
Mutated genes
Select a gene to see the variants recorded for this line.
Gene expression
Show all values
| Gene | Expression |
|---|
Expression measured across the Champions panel.
Lumin data
Request this cell line
Let's build the right study, together.
Backed by deep expertise in these models, our team will work with you to design the study around your target, line of therapy, and endpoint.